| Trial ID: | L7335 |
| Source ID: | NCT01863147
|
| Associated Drug: |
Sitagliptin And Acarbose
|
| Title: |
Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Newly Diagnosed Type 2 Diabetes|Coronary Artery Disease
|
| Interventions: |
DRUG: Sitagliptin and acarbose
|
| Outcome Measures: |
Primary: Left ventricular mass and left ventricular volume, Cardiac magnetic resonance (CMR) imaging was performed at baseline and at 12 months for left ventricular mass and left ventricular volume., 2013~2014(follow up 1 year) | Secondary: Endothelial function and augmentation index (AIx), 1. Endothelial function was assessed on three visits (baseline, month 6, and month 12) by measuring flow-mediated dilation (FMD) of the brachial artery in response to hyperemia according to our previous reports. 2. Pulse wave analysis and pulse wave velocity (PWV) were measured at baseline, 6 months visit, and 12 months visit., 2013~2014 (follow up 1 year)
|
| Sponsor/Collaborators: |
Sponsor: Wuhan General Hospital of Guangzhou Military Command
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
66
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2013-07
|
| Completion Date: |
2015-07
|
| Results First Posted: |
|
| Last Update Posted: |
2015-08-18
|
| Locations: |
Guangda Xiang, Wuhan, Hubei, 430070, China|Wuhan General Hospital, Wuhan, Hubei, 430070, China
|
| URL: |
https://clinicaltrials.gov/show/NCT01863147
|
